Therapeutic manipulations of the B-7 : CD28 : CD152 costimulatory and inhibitory pathways may provide a potential avenue for increasing T-cell responses in B-CLL patients. This evidence concerns the gene CD28 and B-cell chronic lymphocytic leukemia.